Literature DB >> 25288745

Human TLR10 is an anti-inflammatory pattern-recognition receptor.

Marije Oosting1, Shih-Chin Cheng1, Judith M Bolscher2, Rachel Vestering-Stenger1, Theo S Plantinga1, Ineke C Verschueren1, Peer Arts3, Anja Garritsen2, Hans van Eenennaam2, Patrick Sturm4, Bart-Jan Kullberg1, Alexander Hoischen3, Gosse J Adema5, Jos W M van der Meer1, Mihai G Netea1, Leo A B Joosten6.   

Abstract

Toll-like receptor (TLR)10 is the only pattern-recognition receptor without known ligand specificity and biological function. We demonstrate that TLR10 is a modulatory receptor with mainly inhibitory effects. Blocking TLR10 by antagonistic antibodies enhanced proinflammatory cytokine production, including IL-1β, specifically after exposure to TLR2 ligands. Blocking TLR10 after stimulation of peripheral blood mononuclear cells with pam3CSK4 (Pam3Cys) led to production of 2,065 ± 106 pg/mL IL-1β (mean ± SEM) in comparison with 1,043 ± 51 pg/mL IL-1β after addition of nonspecific IgG antibodies. Several mechanisms mediate the modulatory effects of TLR10: on the one hand, cotransfection in human cell lines showed that TLR10 acts as an inhibitory receptor when forming heterodimers with TLR2; on the other hand, cross-linking experiments showed specific induction of the anti-inflammatory cytokine IL-1 receptor antagonist (IL-1Ra, 16 ± 1.7 ng/mL, mean ± SEM). After cross-linking anti-TLR10 antibody, no production of IL-1β and other proinflammatory cytokines could be found. Furthermore, individuals bearing TLR10 polymorphisms displayed an increased capacity to produce IL-1β, TNF-α, and IL-6 upon ligation of TLR2, in a gene-dose-dependent manner. The modulatory effects of TLR10 are complex, involving at least several mechanisms: there is competition for ligands or for the formation of heterodimer receptors with TLR2, as well as PI3K/Akt-mediated induction of the anti-inflammatory cytokine IL-1Ra. Finally, transgenic mice expressing human TLR10 produced fewer cytokines when challenged with a TLR2 agonist. In conclusion, to our knowledge we demonstrate for the first time that TLR10 is a modulatory pattern-recognition receptor with mainly inhibitory properties.

Entities:  

Keywords:  SNPs; TLR10; cytokines; immunology

Mesh:

Substances:

Year:  2014        PMID: 25288745      PMCID: PMC4210319          DOI: 10.1073/pnas.1410293111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

Review 1.  Toll-like receptor signalling.

Authors:  Shizuo Akira; Kiyoshi Takeda
Journal:  Nat Rev Immunol       Date:  2004-07       Impact factor: 53.106

2.  The production of IL-1 receptor antagonist in IFN-beta-stimulated human monocytes depends on the activation of phosphatidylinositol 3-kinase but not of STAT1.

Authors:  Nicolas Molnarfi; Nevila Hyka-Nouspikel; Lyssia Gruaz; Jean-Michel Dayer; Danielle Burger
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

3.  Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2.

Authors:  M Hirschfeld; C J Kirschning; R Schwandner; H Wesche; J H Weis; R M Wooten; J J Weis
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

4.  Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88.

Authors:  Uzma Hasan; Claire Chaffois; Claude Gaillard; Virginie Saulnier; Estelle Merck; Sandra Tancredi; Chantal Guiet; Francine Brière; Jaromir Vlach; Serge Lebecque; Giorgio Trinchieri; Elizabeth E M Bates
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

5.  Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor.

Authors:  J Nigou; C Zelle-Rieser; M Gilleron; M Thurnher; G Puzo
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

6.  Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages.

Authors:  M Hirschfeld; J J Weis; V Toshchakov; C A Salkowski; M J Cody; D C Ward; N Qureshi; S M Michalek; S N Vogel
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

7.  Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.

Authors:  Veit Hornung; Simon Rothenfusser; Stefanie Britsch; Anne Krug; Bernd Jahrsdörfer; Thomas Giese; Stefan Endres; Gunther Hartmann
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

8.  Identification of TLR10 as a key mediator of the inflammatory response to Listeria monocytogenes in intestinal epithelial cells and macrophages.

Authors:  Tim Regan; Ken Nally; Ruaidhri Carmody; Aileen Houston; Fergus Shanahan; John Macsharry; Elizabeth Brint
Journal:  J Immunol       Date:  2013-11-06       Impact factor: 5.422

9.  Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand.

Authors:  Hiroyuki Nagase; Shu Okugawa; Yasuo Ota; Masao Yamaguchi; Hideyuki Tomizawa; Kouji Matsushima; Ken Ohta; Kazuhiko Yamamoto; Koichi Hirai
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

10.  Mycobacteria target DC-SIGN to suppress dendritic cell function.

Authors:  Teunis B H Geijtenbeek; Sandra J Van Vliet; Estella A Koppel; Marta Sanchez-Hernandez; Christine M J E Vandenbroucke-Grauls; Ben Appelmelk; Yvette Van Kooyk
Journal:  J Exp Med       Date:  2003-01-06       Impact factor: 14.307

View more
  88 in total

Review 1.  The critical role of toll-like receptors--From microbial recognition to autoimmunity: A comprehensive review.

Authors:  Maximiliano Javier Jiménez-Dalmaroni; M Eric Gerswhin; Iannis E Adamopoulos
Journal:  Autoimmun Rev       Date:  2015-08-20       Impact factor: 9.754

Review 2.  Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.

Authors:  Martina Musella; Gwenola Manic; Ruggero De Maria; Ilio Vitale; Antonella Sistigu
Journal:  Oncoimmunology       Date:  2017-04-05       Impact factor: 8.110

3.  Toll-like receptors 4, 5, 6 and 7 are constitutively expressed in non-human primate retinal neurons.

Authors:  Monica M Sauter; Aaron W Kolb; Curtis R Brandt
Journal:  J Neuroimmunol       Date:  2018-06-11       Impact factor: 3.478

Review 4.  Toll-like receptor signaling in primary immune deficiencies.

Authors:  Paul J Maglione; Noa Simchoni; Charlotte Cunningham-Rundles
Journal:  Ann N Y Acad Sci       Date:  2015-04-30       Impact factor: 5.691

Review 5.  Understanding the Role of Innate Immunity in the Response to Intracortical Microelectrodes.

Authors:  John K Hermann; Jeffrey R Capadona
Journal:  Crit Rev Biomed Eng       Date:  2018

6.  TLR10 suppresses the activation and differentiation of monocytes with effects on DC-mediated adaptive immune responses.

Authors:  Nicholas J Hess; Christopher Felicelli; Jennifer Grage; Richard I Tapping
Journal:  J Leukoc Biol       Date:  2017-02-24       Impact factor: 4.962

Review 7.  The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies.

Authors:  Anna Warden; Emma Erickson; Gizelle Robinson; R Adron Harris; R Dayne Mayfield
Journal:  Pharmacogenomics       Date:  2016-12-05       Impact factor: 2.533

Review 8.  Toll-like receptors and chronic inflammation in rheumatic diseases: new developments.

Authors:  Leo A B Joosten; Shahla Abdollahi-Roodsaz; Charles A Dinarello; Luke O'Neill; Mihai G Netea
Journal:  Nat Rev Rheumatol       Date:  2016-05-12       Impact factor: 20.543

Review 9.  Epigenetics and innate immunity: the 'unTolld' story.

Authors:  Conor Hennessy; Declan P McKernan
Journal:  Immunol Cell Biol       Date:  2016-02-29       Impact factor: 5.126

Review 10.  Activation and pathogenic manipulation of the sensors of the innate immune system.

Authors:  Charlotte Odendall; Jonathan C Kagan
Journal:  Microbes Infect       Date:  2017-01-14       Impact factor: 2.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.